Optimind Pharma Corp.

Recent News

  • Optimind Acquires MindSetting Institute to Integrate Three-Pronged Approach to its Business and Become Industry Leader in Psychedelic Enhanced Psychotherapy

    Toronto, Ontario--(Newsfile Corp. - September 20, 2022) - Optimind Pharma Corp. (CSE: OMND) ("Optimind" or the "Company") an emerging provider of psychedelic therapies focused on improving the everyday quality of life for individuals who suffer from PTSD, anxiety, depression, and other mental illnesses or disabilities announces today its acquisition of MindSetting Institute, a leader in psychedelic enhanced therapy training and educational programming.The completion of this acquisition introduces a new market opportunity for Optimind which will generate new revenue streams and...

    2022-09-20 8:31 AM EDT
  • Optimind Provides Update on Health Canada's Dealer License Under Joint-Venture with Manitari Pharma

    Toronto, Ontario--(Newsfile Corp. - August 10, 2022) - Optimind Pharma Corp. (CSE:OMND ("Optimind" or the "Company"), an emerging provider of psychedelic therapies, today provides an update on the Company's joint venture with Manitari Pharma Corporation ("Manitari Pharma"), which is 40% owned by Optimind. Manitari Pharma, which has submitted an application to Health Canada for a Controlled Substances Dealer's License for Psilocybin Research Purposes, has begun the process of permitting and planning the build-out of its facility in accordance with the...

    2022-08-10 8:31 AM EDT
  • Optimind Pharma Commences Trading on The CSE Under Ticker Symbol OMND

    Toronto, Ontario--(Newsfile Corp. - August 4, 2022) - Optimind Pharma Corp. (CSE: OMND) ("Optimind" or the "Company") today announced its commencement of trading on the CSE (Canadian Securities Exchange) under ticker symbol "OMND".Optimind specializes in prescribing medical cannabis and other alternative treatments for various medical ailments. Optimind prides itself on providing quality education and health care to patients. Medical cannabis has quickly become one of the most prescribed medications in Canada due to its efficacy and safety profile, which remains...

    2022-08-04 8:31 AM EDT
  • Optimind Pharma Announces Closing of Reverse Takeover Transaction

    Toronto, Ontario--(Newsfile Corp. - July 29, 2022) - Optimind Pharma Corp. ("Optimind" or the "Company") announces the successful closing of its previously announced reverse takeover ("RTO") of Loon Energy Corporation ("Loon") by Optimind Pharma Inc.In connection with the RTO transaction, a wholly-owned subsidiary of Loon amalgamated with and into Optimind Pharma Inc., and all of the outstanding shares of Optimind Pharma Inc. were exchanged for shares of Loon, and Loon changed its name to "Optimind Pharma Corp." and consolidated its...

    2022-07-29 8:00 AM EDT